Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis.

Kato KC, de Morais-Teixeira E, Islam A, Leite MF, Demicheli C, de Castro WV, Corrêa-Junior JD, Rabello A, Frézard F.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00539-18. doi: 10.1128/AAC.00539-18. Print 2018 Aug.

2.

Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.

Lanza JS, Fernandes FR, Corrêa-Júnior JD, Vilela JM, Magalhães-Paniago R, Ferreira LA, Andrade MS, Demicheli C, Melo MN, Frézard F.

Int J Nanomedicine. 2016 May 25;11:2305-18. doi: 10.2147/IJN.S105952. eCollection 2016.

3.

Silver and Nitrate Oppositely Modulate Antimony Susceptibility through Aquaglyceroporin 1 in Leishmania (Viannia) Species.

Andrade JM, Baba EH, Machado-de-Avila RA, Chavez-Olortegui C, Demicheli CP, Frézard F, Monte-Neto RL, Murta SM.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4482-9. doi: 10.1128/AAC.00768-16. Print 2016 Aug.

4.

Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines.

Islam A, Rodrigues BL, Marzano IM, Perreira-Maia EC, Dittz D, Paz Lopes MT, Ishfaq M, Frézard F, Demicheli C.

Eur J Med Chem. 2016 Feb 15;109:254-67. doi: 10.1016/j.ejmech.2016.01.003. Epub 2016 Jan 7.

PMID:
26774931
5.

Gadolinium(III) Complexes with N-Alkyl-N-methylglucamine Surfactants Incorporated into Liposomes as Potential MRI Contrast Agents.

Silva SR, Duarte ÉC, Ramos GS, Kock FV, Andrade FD, Frézard F, Colnago LA, Demicheli C.

Bioinorg Chem Appl. 2015;2015:942147. doi: 10.1155/2015/942147. Epub 2015 Aug 10.

6.

Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite.

Gomes ML, DeFreitas-Silva G, dos Reis PG, Melo MN, Frézard F, Demicheli C, Idemori YM.

J Biol Inorg Chem. 2015 Jul;20(5):771-9. doi: 10.1007/s00775-015-1264-4. Epub 2015 May 1.

PMID:
25929728
7.

Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.

Azevedo EG, Ribeiro RR, da Silva SM, Ferreira CS, de Souza LE, Ferreira AA, de Oliveira E Castro RA, Demicheli C, Rezende SA, Frézard F.

Expert Opin Drug Deliv. 2014 Oct;11(10):1551-60. doi: 10.1517/17425247.2014.932347. Epub 2014 Jun 25.

PMID:
24962630
8.

Novel triphenylantimony(V) and triphenylbismuth(V) complexes with benzoic acid derivatives: structural characterization, in vitro antileishmanial and antibacterial activities and cytotoxicity against macrophages.

Islam A, Da Silva JG, Berbet FM, da Silva SM, Rodrigues BL, Beraldo H, Melo MN, Frézard F, Demicheli C.

Molecules. 2014 May 12;19(5):6009-30. doi: 10.3390/molecules19056009.

9.

Mixed antimony(V) complexes with different sugars to modulate the oral bioavailability of pentavalent antimonial drugs.

Ferreira WA, Islam A, Andrade AP, Fernandes FR, Frézard F, Demicheli C.

Molecules. 2014 Apr 28;19(5):5478-89. doi: 10.3390/molecules19055478.

10.

Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites.

Lizarazo-Jaimes EH, Reis PG, Bezerra FM, Rodrigues BL, Monte-Neto RL, Melo MN, Frézard F, Demicheli C.

J Inorg Biochem. 2014 Mar;132:30-6. doi: 10.1016/j.jinorgbio.2013.12.001. Epub 2013 Dec 19.

PMID:
24412095
11.

Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.

Kato KC, Morais-Teixeira E, Reis PG, Silva-Barcellos NM, Salaün P, Campos PP, Dias Corrêa-Junior J, Rabello A, Demicheli C, Frézard F.

Antimicrob Agents Chemother. 2014;58(1):481-8. doi: 10.1128/AAC.01499-13. Epub 2013 Nov 4.

12.

Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis.

Fernandes FR, Ferreira WA, Campos MA, Ramos GS, Kato KC, Almeida GG, Corrêa JD Junior, Melo MN, Demicheli C, Frézard F.

Antimicrob Agents Chemother. 2013 Sep;57(9):4229-4236. doi: 10.1128/AAC.00639-13. Epub 2013 Jun 24.

13.

Cytotoxicity and In Vitro Antileishmanial Activity of Antimony (V), Bismuth (V), and Tin (IV) Complexes of Lapachol.

Rocha MN, Nogueira PM, Demicheli C, de Oliveira LG, da Silva MM, Frézard F, Melo MN, Soares RP.

Bioinorg Chem Appl. 2013;2013:961783. doi: 10.1155/2013/961783. Epub 2013 May 25.

14.

Improved antileishmanial activity of Dppz through complexation with antimony(III) and bismuth(III): investigation of the role of the metal.

Lizarazo-Jaimes EH, Monte-Neto RL, Reis PG, Fernandes NG, Speziali NL, Melo MN, Frézard F, Demicheli C.

Molecules. 2012 Oct 25;17(11):12622-35. doi: 10.3390/molecules171112622.

15.

Greater binding affinity of trivalent antimony to a CCCH zinc finger domain compared to a CCHC domain of kinetoplastid proteins.

Frézard F, Silva H, Pimenta AM, Farrell N, Demicheli C.

Metallomics. 2012 May;4(5):433-40. doi: 10.1039/c2mt00176d. Epub 2012 Mar 27.

PMID:
22454083
16.

Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.

da Silva SM, Amorim IF, Ribeiro RR, Azevedo EG, Demicheli C, Melo MN, Tafuri WL, Gontijo NF, Michalick MS, Frézard F.

Antimicrob Agents Chemother. 2012 Jun;56(6):2858-67. doi: 10.1128/AAC.00208-12. Epub 2012 Mar 12.

17.

Antimony(V) and bismuth(V) complexes of lapachol: synthesis, crystal structure and cytotoxic activity.

Oliveira LG, Silva MM, Paula FC, Pereira-Maia EC, Donnici CL, Simone CA, Frézard F, Silva EN Jr, Demicheli C.

Molecules. 2011 Dec 13;16(12):10314-23. doi: 10.3390/molecules161210314.

18.

Interaction of arsenite with a zinc finger CCHC peptide: evidence for formation of an As-Zn-peptide mixed complex.

Demicheli C, Frézard F, Pereira FA, Santos DM, Mangrum JB, Farrell NP.

J Inorg Biochem. 2011 Dec;105(12):1753-8. doi: 10.1016/j.jinorgbio.2011.09.023. Epub 2011 Sep 22.

PMID:
22099473
19.

New delivery strategies for the old pentavalent antimonial drugs.

Frézard F, Demicheli C.

Expert Opin Drug Deliv. 2010 Dec;7(12):1343-58. doi: 10.1517/17425247.2010.529897. Epub 2010 Oct 28. Review.

PMID:
21029028
20.

Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimoniate-beta-cyclodextrin conjugates.

Ribeiro RR, Ferreira WA, Martins PS, Neto RL, Rocha OG, Le Moyec L, Demicheli C, Frézard F.

Biopharm Drug Dispos. 2010 Mar;31(2-3):109-19. doi: 10.1002/bdd.695.

PMID:
20014042

Supplemental Content

Loading ...
Support Center